TrialThe Journal of experimental medicine2016

Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.

Aude G Chapuis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.